Zealand presented on its dual acting peptides at the New York Academy of Sciences’ meeting GLP-1 Treatment for Diabetes and Beyond

Copenhagen, 2015-12-09 09:20 CET (GLOBE NEWSWIRE) –Acting Senior Vice President of Research Keld Fosgerau presented key examples of Zealand’s novel GLP-1 based dual acting peptides to address unmet medical needs in the treatment of Type 2 diabetes and obesity